Cybin Inc. Common Stock Cybin Inc. Common Stock

Cybin Inc. Common Stock

HELP

Rank in Stocks #11772
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Share Price
$6.89
Last synced: 2026-11-18
Market Cap
$503.43M
Change (1 day)
-4.31%
Change (1 year)
-
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
P/S ratio for Cybin Inc. Common Stock (HELP)
P/S ratio as of November 2026 TTM: 0.00
According to Cybin Inc. Common Stock's latest financial reports and stock price, its current price-to-sales ratio (TTM) is 0.00. At the end of 2025 the company had a P/S ratio of 0.00.
P/S ratio history for Cybin Inc. Common Stock from 2017 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 -100.00%
2021 5.94K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.51 -
US
35.79 -
US
4.19 -
AU
6.63 -
BE
13.60 -
NL

Questions about Cybin Inc. Common Stock's P/S ratio

What was Cybin Inc. Common Stock's P/S ratio in 2025?

In 2025, Cybin Inc. Common Stock's P/S ratio was 0.00, compared with 0.00 in 2024.

How has Cybin Inc. Common Stock's P/S ratio changed since 2020?

From 2020 to 2025, Cybin Inc. Common Stock's P/S ratio was highest in 2021 (5.94K) and lowest in 2025 (0.00).

How does Cybin Inc. Common Stock's P/S ratio compare with similar companies?

Cybin Inc. Common Stock's P/S ratio (0.00) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 35.79.